Activators of PKM2 in cancer metabolism

Future Medicinal Chemistry

Volumn 6, Issue 10, 2014, Pages 1167-1178

  Warner, Steven L ^a   Carpenter, Kent J ^a   Bearss, David J ^a  

^a Tolero Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ENZYME ACTIVATOR; PYRUVATE KINASE; PYRUVATE KINASE 1; PYRUVATE KINASE 2; PYRUVATE KINASE 2 ACTIVATOR; UNCLASSIFIED DRUG; CARRIER PROTEIN; MEMBRANE PROTEIN; MOLECULAR LIBRARY; THYROID HORMONE; THYROID HORMONE-BINDING PROTEINS;

ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER CELL METABOLISM; CELL METABOLISM; ENZYME ACTIVITY; ENZYME REGULATION; M PHASE CELL CYCLE CHECKPOINT; NUCLEAR REPROGRAMMING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; AGONISTS; ANIMAL; CHEMISTRY; DRUG DEVELOPMENT; ENZYMOLOGY; GENETICS; HUMAN; METABOLISM; MOLECULAR LIBRARY; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PHARMACOLOGY; THERAPEUTIC USE;

ANIMALS; ANTINEOPLASTIC AGENTS; CARRIER PROTEINS; DRUG DISCOVERY; HUMANS; MEMBRANE PROTEINS; MOLECULAR TARGETED THERAPY; NEOPLASMS; SMALL MOLECULE LIBRARIES; THYROID HORMONES;

EID: 84905507518     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.14.70     Document Type: Review

References (50)

1. Warburg O. On the origin of cancer cells. Science 123(3191), 309-314 (1956
2. Mazurek S. Pyruvate kinase type M2: A key regulator of the metabolic budget system in tumor cells. Int. J. Biochem. Cell Biol. 43(7), 969-980 (2011
3. Vander Heiden MG, Locasale JW, Swanson KD et al. Evidence for an alternative glycolytic pathway in rapidly proliferating cells. Science 329(5998), 1492-1499 (2010
4. Lee J, Kim HK, Han YM, Kim J. Pyruvate kinase isozyme type M2 (PKM2) interacts and cooperates with Oct-4 in regulating transcription. Int. J. Biochem. Cell Biol. 40(5), 1043-1054 (2008
5. Prigione A, Rohwer N, Hoffmann S et al HIF1alpha modulates cell fate reprogramming through early glycolytic shift and upregulation of PDK1-3 and PKM2. Stem Cells 32(2), 364-376 (2014
6. Ashizawa K, Willingham MC, Liang CM, Cheng SY. In vivo regulation of monomer-Tetramer conversion of pyruvate kinase subtype M2 by glucose is mediated via fructose 1, 6-bisphosphate. J. Biol. Chem. 266(25), 16842-16846 (1991
7. Lv L, Xu YP, Zhao D et al. Mitogenic and oncogenic stimulation of K433 acetylation promotes PKM2 protein kinase activity and nuclear localization. Mol. Cell 52(3), 340-352 (2013
8. Chiavarina B, Whitaker-Menezes D, Martinez-Outschoorn UE et al. Pyruvate kinase expression (PKM1 and PKM2) in cancer-Associated fibroblasts drives stromal nutrient production and tumor growth. Cancer Biol. Ther. 12(12), 1101-1113 (2011
9. Duvel K, Yecies JL, Menon S et al. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol. Cell 39(2), 171-183 (2010
10. Eigenbrodt E, Leib S, Kramer W, Friis RR, Schoner W. Structural and kinetic differences between the M2 type pyruvate kinases from lung and various tumors. Biomed. Biochim. Acta 42(11-12), S278-S282 (1983
11. David CJ, Chen M, Assanah M, Canoll P, Manley JL. HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature 463(7279), 364-368 (2010
12. Toschi A, Lee E, Thompson S et al. Phospholipase D-mTOR requirement for the Warburg effect in human cancer cells. Cancer Lett. 299(1), 72-79 (2010
13. Christofk HR, Vander Heiden MG, Harris MH et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452(7184), 230-233 (2008
14. Chaneton B, Hillmann P, Zheng L et al Serine is a natural ligand and allosteric activator of pyruvate kinase M2. Nature 491(7424), 458-462 (2012
15. Carminatti H, Jimenez De Asua L, Leiderman B, Rozengurt E. Allosteric properties of skeletal muscle pyruvate kinase. J. Biol. Chem. 246(23), 7284-7288 (1971
16. Elbers JR, Van Unnik JA, Rijksen G et al. Pyruvate kinase activity and isozyme composition in normal fibrous tissue and fibroblastic proliferations. Cancer 67(10), 2552-2559 (1991
17. Kosugi M, Ahmad R, Alam M, Uchida Y, Kufe D. MUC1-C oncoprotein regulates glycolysis and pyruvate kinase M2 activity in cancer cells. PLoS ONE 6(11), e28234 (2011
18. Ye J, Mancuso A, Tong X et al. Pyruvate kinase M2 promotes de novo serine synthesis to sustain mTORC1 activity and cell proliferation. Proc. Natl Acad. Sci. USA 109(18), 6904-6909 (2012
19. Locasale JW, Cantley LC. Genetic selection for enhanced serine metabolism in cancer development. Cell Cycle 10(22), 3812-3813 (2011
20. Lv L, Li D, Zhao D et al. Acetylation targets the M2 isoform of pyruvate kinase for degradation through chaperonemediated autophagy and promotes tumor growth. Mol. Cell 42(6), 719-730 (2011
21. Goldberg MS, Sharp PA. Pyruvate kinase M2-specific siRNA induces apoptosis and tumor regression. J. Exp. Med. 209(2), 217-224 (2012
22. Zwerschke W, Mazurek S, Massimi P, Banks L, Eigenbrodt E, Jansen-Durr P. Modulation of type M2 pyruvate kinase activity by the human papillomavirus type 16 E7 oncoprotein. Proc. Natl Acad. Sci. USA 96(4), 1291-1296 (1999
23. Hitosugi T, Kang S, Vander Heiden MG et al. Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci. Signal. 2(97), ra73 (2009
24. Presek P, Reinacher M, Eigenbrodt E. Pyruvate kinase type M2 is phosphorylated at tyrosine residues in cells transformed by Rous sarcoma virus. FEBS Lett. 242(1), 194-198 (1988
25. Anastasiou D, Poulogiannis G, Asara JM et al. Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses. Science 334(6060), 1278-1283 (2011
26. Chen N, Rinner O, Czernik D et al. The oxygen sensor PHD3 limits glycolysis under hypoxia via direct binding to pyruvate kinase. Cell Res. 21(6), 983-986 (2011
27. Yu Z, Zhao X, Huang L et al. Proviral insertion in murine lymphomas 2 (PIM2) oncogene phosphorylates pyruvate kinase M2 (PKM2) and promotes glycolysis in cancer cells. J. Biol. Chem. 288(49), 35406-35416 (2013
28. Wang HJ, Hsieh YJ, Cheng WC et al. JMJD5 regulates PKM2 nuclear translocation and reprograms HIF-1alphamediated glucose metabolism. Proc. Natl Acad. Sci. USA 111(1), 279-284 (2014
29. Mazurek S, Boschek CB, Hugo F, Eigenbrodt E. Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin. Cancer Biol. 15(4), 300-308 (2005
30. Yang W, Lu Z. Nuclear PKM2 regulates the Warburg effect. Cell Cycle 12(19), 3154-3158 (2013
31. Yang W, Zheng Y, Xia Y et al. ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect. Nat. Cell Biol. 14(12), 1295-1304 (2012
32. Iqbal MA, Siddiqui FA, Chaman N et al. Missense mutations in pyruvate kinase M2 promote cancer metabolism, oxidative endurance, anchorage independence and tumor growth in a dominant negative manner. J. Biol. Chem. 289(12), 8098-8105 (2014
33. Robey IF, Lien AD, Welsh SJ, Baggett BK, Gillies RJ. Hypoxia-inducible factor-1alpha and the glycolytic phenotype in tumors. Neoplasia 7(4), 324-330 (2005
34. Gao X, Wang H, Yang JJ, Liu X, Liu ZR. Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase. Mol. Cell 45(5), 598-609 (2012
35. Zhang X, He C, He C et al. Nuclear PKM2 expression predicts poor prognosis in patients with esophageal squamous cell carcinoma. Pathol. Res. Pract. 209(8), 510-515 (2013
36. Jiang Y, Li X, Yang W et al. PKM2 regulates chromosome segregation and mitosis progression of tumor cells. Mol. Cell 53(1), 75-87 (2014
37. Spoden GA, Rostek U, Lechner S, Mitterberger M, Mazurek S, Zwerschke W. Pyruvate kinase isoenzyme M2 is a glycolytic sensor differentially regulating cell proliferation, cell size and apoptotic cell death dependent on glucose supply. Exp. Cell Res. 315(16), 2765-2774 (2009
38. Vander Heiden MG, Christofk HR, Schuman E et al. Identification of small molecule inhibitors of pyruvate kinase M2. Biochem. Pharmacol. 79(8), 1118-1124 (2010
39. Jung Y, Jang YJ, Kang MH et al. Metabolic signature genes associated with susceptibility to pyruvate kinase, muscle type 2 gene ablation in cancer cells. Mol. Cells 35(4), 335-341 (2013
40. Blouin MJ, Zhao Y, Zakikhani M, Algire C, Piura E, Pollak M. Loss of function of PTEN alters the relationship between glucose concentration and cell proliferation, increases glycolysis, and sensitizes cells to 2-deoxyglucose. Cancer Lett. 289(2), 246-253 (2010
41. Dombrauckas JD, Santarsiero BD, Mesecar AD. Structural basis for tumor pyruvate kinase M2 allosteric regulation and catalysis. Biochemistry 44(27), 9417-9429 (2005
42. Xu Y, Liu XH, Saunders M et al. Discovery of 3-(trifluoromethyl)-1H- pyrazole-5-carboxamide activators of the M2 isoform of pyruvate kinase (PKM2). Bioorg. Med. Chem. Lett. 24(2), 515-519 (2014
43. Parnell KM, Foulks JM, Nix RN et al. Pharmacologic activation of PKM2 slows lung tumor xenograft growth. Mol. Cancer Ther. 12(8), 1453-1460 (2013
44. Anastasiou D, Yu Y, Israelsen WJ et al. Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis. Nat. Chem. Biol. 8(10), 839-847 (2012
45. Kung C, Hixon J, Choe S et al. Small molecule activation of PKM2 in cancer cells induces serine auxotrophy. Chem. Biol. 19(9), 1187-1198 (2012
46. Guo C, Linton A, Jalaie M et al. Discovery of 2-((1H-benzo[d]imidazol-1- yl)methyl)-4H-pyrido[1, 2-A] pyrimidin-4-ones as novel PKM2 activators. Bioorg. Med. Chem. Lett. 23(11), 3358-3363 (2013
47. Boxer MB, Jiang JK, Vander Heiden MG et al. Evaluation of substituted N, N'-diarylsulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase. J. Med. Chem. 53(3), 1048-1055 (2010
48. Jiang JK, Boxer MB, Vander Heiden MG et al. Evaluation of thieno[3, 2-b]pyrrole[3, 2-d]pyridazinones as activators of the tumor cell specific M2 isoform of pyruvate kinase. Bioorg. Med. Chem. Lett. 20(11), 3387-3393 (2010
49. Walsh MJ, Brimacombe KR, Veith H et al. 2-oxo-N-Aryl-1, 2, 3, 4-Tetrahydroquinoline-6-sulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase. Bioorg. Med. Chem. Lett. 21(21), 6322-6327 (2011
50. Yacovan A, Ozeri R, Kehat T et al. 1-(sulfonyl)-5-(arylsulfonyl)indoline as activators of the tumor cell specific M2 isoform of pyruvate kinase. Bioorg. Med. Chem. Lett. 22(20), 6460-6468 (2012.